Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) Director Kush Parmar sold 92,444 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $7.00, for a total transaction of $647,108.00. Following the completion of the sale, the director directly owned 2,691,337 shares of the company’s stock, valued at $18,839,359. The trade was a 3.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Kush Parmar also recently made the following trade(s):
- On Friday, August 7th, Kush Parmar sold 52,317 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.85, for a total transaction of $358,371.45.
- On Thursday, August 6th, Kush Parmar sold 10,494 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.00, for a total value of $73,458.00.
- On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.85, for a total value of $11,768.30.
- On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.93, for a total value of $795,259.08.
Entrada Therapeutics Trading Up 1.2%
Shares of TRDA traded up $0.08 during midday trading on Monday, reaching $6.95. 411,770 shares of the company were exchanged, compared to its average volume of 464,800. Entrada Therapeutics, Inc. has a 1-year low of $4.93 and a 1-year high of $16.45. The stock has a 50-day moving average price of $6.86 and a 200-day moving average price of $9.68. The company has a market cap of $270.63 million, a price-to-earnings ratio of -1.76 and a beta of -0.26.
Analyst Ratings Changes
Several brokerages have recently weighed in on TRDA. Guggenheim lowered their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 8th. HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Roth Capital set a $10.00 price objective on Entrada Therapeutics in a research note on Friday, May 8th. Finally, Weiss Ratings downgraded Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $17.50.
Get Our Latest Analysis on Entrada Therapeutics
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in TRDA. BlackRock Inc. bought a new position in shares of Entrada Therapeutics in the 2nd quarter worth about $19,013,000. Millennium Management LLC raised its stake in Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after acquiring an additional 666,287 shares during the period. Citadel Advisors LLC lifted its holdings in Entrada Therapeutics by 234.5% in the third quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock worth $1,947,000 after acquiring an additional 235,384 shares during the last quarter. Baker BROS. Advisors LP lifted its holdings in Entrada Therapeutics by 4.3% in the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after acquiring an additional 206,911 shares during the last quarter. Finally, Qube Research & Technologies Ltd boosted its stake in Entrada Therapeutics by 115.3% in the third quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock valued at $1,670,000 after acquiring an additional 154,143 shares during the period. 86.39% of the stock is owned by institutional investors and hedge funds.
About Entrada Therapeutics
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Read More
- Five stocks we like better than Entrada Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
